Comprehensive Insights of Global Cyclin-Dependent Kinase Inhibitor Pipeline
18 juin 2024 10h17 HE
|
Research and Markets
Dublin, June 18, 2024 (GLOBE NEWSWIRE) -- The "Cyclin-Dependent Kinase Inhibitor - Pipeline Insight, 2024" report has been added to ResearchAndMarkets.com's offering.The detailed report furnishes...
CAR-T Therapy Pipeline Landscape Report, 2024 - Features Insights on Emerging Drugs CT053, Descartes-08, ALLO-501A, CTX110, and IMPT 314
14 juin 2024 06h23 HE
|
Research and Markets
Dublin, June 14, 2024 (GLOBE NEWSWIRE) -- The "CAR-T Therapy - Pipeline Insight, 2024" report has been added to ResearchAndMarkets.com's offering.This report provides in-depth insights into the...
Provectus Biopharmaceuticals Announces Investor Webinar for 2024 Annual Meeting of Stockholders
13 juin 2024 08h00 HE
|
Provectus Biopharmaceuticals Inc.
KNOXVILLE, Tenn., June 13, 2024 (GLOBE NEWSWIRE) -- Provectus Biopharmaceuticals, Inc. (“Provectus” or the “Company”) (OTCQB: PVCT) announced today that its 2024 annual stockholder meeting (the...
Chemotherapy-Induced Anemia Pipeline Insights Report, 2024 Featuring Analysis of Roxadustat (FibroGen), SPP-003 (SBI Pharmaceuticals), and More
31 mai 2024 06h26 HE
|
Research and Markets
Dublin, May 31, 2024 (GLOBE NEWSWIRE) -- The "Chemotherapy-Induced Anemia - Pipeline Insight, 2024" clinical trials has been added to ResearchAndMarkets.com's offering.This report provides...
Global Pharmaceutical Industry Outlook 2024: Key Growth Opportunities in Scaling Precision Oncology in Asia-Pacific Through Public-private Partnership Models
27 mai 2024 04h33 HE
|
Research and Markets
Dublin, May 27, 2024 (GLOBE NEWSWIRE) -- The "Global Pharmaceutical Industry Outlook, 2024" report has been added to ResearchAndMarkets.com's offering.The leading trends shaping the global...
Provectus Biopharmaceuticals Announces Notice of Allowance for U.S. Patent of Oral Administration of Rose Bengal Sodium in Hematology (Leukemia)
02 mai 2024 08h00 HE
|
Provectus Biopharmaceuticals Inc.
KNOXVILLE, TN, May 02, 2024 (GLOBE NEWSWIRE) -- Provectus Biopharmaceuticals, Inc. (“Provectus” or the “Company”) (OTCQB: PVCT) today announced that the United States Patent and Trademark Office has...
Pasithea Therapeutics Announces PAS-004 Abstract Accepted for Poster Presentation at 2024 ASCO Annual Meeting
29 avr. 2024 07h59 HE
|
Pasithea
Pasithea Therapeutics' PAS-004 abstract accepted for ASCO poster presentation: novel MEK inhibitor shows promise for NF1 and cancer therapy.
Checkpoint Kinase Inhibitors Pipeline Insight Report, 2024: Analysis of 15+ Companies and 15+ Pipeline Drugs which are Poised to Transform Cancer Therapeutics
26 avr. 2024 09h34 HE
|
Research and Markets
Dublin, April 26, 2024 (GLOBE NEWSWIRE) -- The "Checkpoint Kinase Inhibitors - Pipeline Insight, 2024" report has been added to ResearchAndMarkets.com's offering. As the global healthcare...
NK Cell Therapies Pipeline Report 2024: Insights on 80+ Companies and 100+ Pipeline Drugs, Including ALECSAT (CytoVac), NKTR-214/Bempegaldesleukin (Nektar Therapeutics), and Monalizumab (Innate Pharma)
26 avr. 2024 04h12 HE
|
Research and Markets
Dublin, April 26, 2024 (GLOBE NEWSWIRE) -- The "NK Cell Therapies - Pipeline Insight, 2024" clinical trials has been added to ResearchAndMarkets.com's offering.This report provides comprehensive...
Provectus Biopharmaceuticals Announces Publication of Preclinical Data of Oral Administration of Provectus Rose Bengal for Solid Tumor Cancers
18 avr. 2024 08h00 HE
|
Provectus Biopharmaceuticals Inc.
Research on breast, colorectal, head and neck, and testicular cancersNovel downregulation of WNK1 and Wnt signaling KNOXVILLE, TN, April 18, 2024 (GLOBE NEWSWIRE) -- Provectus Biopharmaceuticals,...